Danaher Corporation (LON:0R2B)
London
· Delayed Price · Currency is GBP · Price in USD 192.12
+3.01 (1.59%)
At close: Jun 3, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 28, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| Diagnostics | 9.71B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostics Growth | -0.20% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Environmental & Applied Solutions | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Environmental & Applied Solutions Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biotechnology | 6.85B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biotechnology Growth | 0.22% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences | 7.26B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences Growth | 1.21% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Recurring | 19.39B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Recurring Growth | 3.04% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Non-Recurring | 4.43B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Non-Recurring Growth | -9.93% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 28, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| Diagnostics Operating Income | 2.51B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostics Operating Income Growth | -1.80% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Environmental & Applied Solutions Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Environmental & Applied Solutions Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biotechnology Operating Income | 1.80B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biotechnology Operating Income Growth | 9.95% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences Operating Income | 845.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences Operating Income Growth | -24.76% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 28, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| North America | 10.25B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North America Growth | 1.01% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Western Europe | 5.48B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Western Europe Growth | 2.16% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Developed Markets | 1.23B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Developed Markets Growth | -1.68% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| High-Growth Markets | 6870000000.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| High-Growth Markets Growth | -1.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2011 - 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2011 - 2019 |
| Core Sales Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Core Sales Growth Ex-Cytiva |
Log In |
Log In |
Log In |
Log In | Upgrade
|